Novacea Terminates Asentar Phase III For Prostate Cancer, But Sees Hope For Treatment In Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Novacea and partner Schering-Plough aim to investigate higher death rate in Asentar arm, move forward in other oncology indications, Novacea CEO says.